Vistide Articles
Actavis confirms generic Exelon Patch patent challenge; InnoPharma debuts generic Vistide in USA
9 March 2013
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
Gilead to donate $1.1M a year to Czech IOCB
24 July 2006
Chimerix gains rights to Gilead's cidofovir
22 September 2003
Chimerix gets $36M NIH grant to develop smallpox therapy
15 September 2003
Healthy revenue growth at Gilead
11 February 2002
OSI acquires oncology assets from Gilead in $200 million deal
27 November 2001
Despite revenue rise, Gilead loss increases
1 May 2001
Gilead Sciences to merge with NeXstar
2 March 1999
Gilead Sciences' revenues
10 February 1999
FDA Approves Isis And CIBA Vision's Vitravene
1 September 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
Mixed Fortunes For US Companies In 1st Qtr
14 May 1998
Fomivirsen Completes Phase III Study
12 February 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Global Anti-HIV Market To Top $5 Billion In 2005
21 January 1998
1998 - A "Critical" Year For P&U, Says CEO
3 December 1997
Gilead 9-Month Sales Driven By Vistide
18 November 1997
US 2nd Qtr Corporate Results Round-Up
7 August 1997
First Launch For P&U's Edronax
31 July 1997
Vistide For CMV Disease Cleared In EU
12 May 1997
New York Stock Comment
12 May 1997
Gilead Sciencs' Forvade Non-Approvable In USA
12 May 1997
US Quarterly Financial Results Round-Up
5 May 1997
"Control" Of CMV Retinitis With Isis Drug
24 February 1997
Strong Earnings Continue At Major US Drug Firms
10 February 1997
NEW YORK STOCK COMMENT
10 February 1997
Progress With Gilead Sciences' Antivirals
3 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
Gilead Sciences Files NDA For Forvade
20 January 1997
NEW YORK STOCK COMMENT
20 January 1997
Gilead's Vistide Cleared By CPMP
6 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
Excellent Year For The Biotechnology Industry
16 December 1996
US Quarterly Results Show Improvements
4 November 1996
Hybridon Antisense Chemistry Reviewed
23 September 1996
European Approval of Vistide By Early 1997?
16 September 1996
New York Stock Comment
16 September 1996
P&U Gains Non-US Rights To Cidofovir
19 August 1996
First Launch Of Gilead's Cidofovir In USA
8 July 1996
Antiviral Activity Seen With Gilead's Cidofovir
3 June 1996
Gilead's Cidofovir Gel For Genital warts
8 April 1996
FDA Panel Backs Gilead's Vistide For CMV Retinitis
25 March 1996
Vistide In France
18 March 1996
Chiron's Vitrasert Approved In Its First Market
11 March 1996
Vistide Review Meeting - Date Set
4 March 1996
Gilead's GS 930
19 February 1996
Gilead: Vistide news
29 January 1996
Gilead and Storz test Gilead nucleoside analogue drug
8 January 1996
Many US Biotech Firms See Good 3rd Qtr Sales Growth
13 November 1995
Gilead Sciences: Vistide latest
16 October 1995
Gilead's Vistide: new trial data
2 October 1995
Gilead Science appointment
4 September 1995
First Results With Gilead's AIDS Treatment
8 May 1995
Gilead's New Products Add To Impressive Pipeline
6 March 1995
Showing 1-57 of 57 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
